The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation.

With ongoing challenges including selectivity and resistance in small molecule inhibitors, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs.

Join 60+ peers at the 3rd Kinase Targeted Drug Discovery Summit; the premier, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology.

• Discover cutting-edge developments in small molecule therapeutics, including PROTACs, molecular glues, and allosteric inhibitors
• Enhance drug selectivity & tackle resistance head-on, and identify optimal combination partners
• Lead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!

Attendance is complimentary for drug developers & researchers (subject to T&Cs) – we’d love to welcome you to Boston in February!